Ni Xiao, Austin Michael, Langridge Timothy, Bojaxhi Pierr, Bijani Pedram, Wang Xiaohong, Duvic Madeleine
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Photodermatol Photoimmunol Photomed. 2020 Jul;36(4):290-298. doi: 10.1111/phpp.12552. Epub 2020 Apr 16.
BACKGROUND/PURPOSE: We previously reported that myeloid dendritic cells (mDC) were increased in patients with leukemic cutaneous T-cell lymphoma (L-CTCL) following extracorporeal photopheresis (ECP) using the Therakos UVAR XTS system. We now assessed monocyte-derived mDCs (Mo-DCs) in L-CTCL patients treated with the CELLEX photopheresis system. CD209, a transmembrane receptor, was used to define Mo-DCs.
Peripheral blood samples from baseline pre-ECP and at Day 2, 1 month, 3 months, and 6 months post-ECP were analyzed by flow cytometry for Lin HLA-DR CD123 plasmacytoid dendritic cells (pDCs), Lin HLA-DR CD11c mDCs, and CD209 mDCs. The expression of CD209 mRNA was assessed by real-time PCR.
At baseline, 7 of 19 patients had lower than normal mDCs, and all patients had lower than normal CD209 mDCs in peripheral blood mononuclear cells (0.005% in patients, n = 19, vs 0.50% in healthy donors, n = 7, P < .0001). The CD209 mDC numbers only accounted for 3.28% out of total mDCs in patients compared with 66.51% in healthy donors. After treatment, the CD209 mDC numbers showed increasing trends in patients. The average absolute numbers of CD209 mDCs went up by 4.8-fold at 3 months (n = 10, P = .103) and by 6.4-fold at 6 months (n = 9, P = .100). CD209 mRNA expression went up in two patients responsive to therapy, parallel to CD209 mDC numbers. L-CTCL patients achieved 70% overall clinical response rate (7/10) following ECP therapy with the CELLEX system.
Our results suggest that the CELLEX photopheresis system is effective for treating L-CTCL patients like the UVAR XTS system, and in vivo-generated Mo-DCs increase following ECP.
背景/目的：我们之前报道过，使用Therakos UVAR XTS系统进行体外光化学疗法（ECP）后，白血病性皮肤T细胞淋巴瘤（L-CTCL）患者的髓样树突状细胞（mDC）数量增加。我们现在评估了使用CELLEX光化学疗法系统治疗的L-CTCL患者中单核细胞来源的mDC（Mo-DC）。跨膜受体CD209被用于定义Mo-DC。
通过流式细胞术分析ECP前基线以及ECP后第2天、1个月、3个月和6个月时的外周血样本，检测Lin HLA-DR CD123浆细胞样树突状细胞（pDC）、Lin HLA-DR CD11c mDC和CD209 mDC。通过实时PCR评估CD209 mRNA的表达。
基线时，19例患者中有7例的mDC低于正常水平，所有患者外周血单核细胞中的CD209 mDC均低于正常水平（患者为0.005%，n = 19；健康供者为0.50%，n = 7，P <.0001）。患者中CD209 mDC数量仅占总mDC的3.28%，而健康供者中这一比例为66.51%。治疗后，患者的CD209 mDC数量呈上升趋势。CD209 mDC的平均绝对数量在3个月时增加了4.8倍（n = 10，P =.103），在6个月时增加了6.4倍（n = 9，P =.100）。两名对治疗有反应的患者中，CD209 mRNA表达增加，与CD209 mDC数量平行。使用CELLEX系统进行ECP治疗后，L-CTCL患者的总体临床缓解率达到70%（7/10）。
我们的结果表明，CELLEX光化学疗法系统与UVAR XTS系统一样，对治疗L-CTCL患者有效，且ECP后体内生成的Mo-DC会增加。
